Co-development Partnering Agreements in Pharma, Biotech & Diagnostics- CP2062 - Apr2015v2
NEW YORK, April 28, 2015 /PRNewswire/ -- The Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies
The Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.
The report provides a detailed understand and analysis of how and why companies enter co-development deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of co-development dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-development as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of co-development deals. The chapter includes numerous case studies to enable understanding of both pure co-development deals and multicomponent deals where co-development forms a part.
Chapter 4 provides a review of the leading co-development deals since 2010. Deals are listed by headline value, signed by big pharma and big biotech, most active big pharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapters 5 and 6 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of co-development contract deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of co-development deals signed and announced since 2010 where a contract document is available. The chapter is organized by A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends and activities in co- development dealmaking since 2010.
In addition, a comprehensive appendix is provided organized by co-development partnering company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about co-development partnering in the research, development and commercialization of technologies and products.
Report scope
Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading life science companies worldwide.
Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 includes:
Trends in co-development dealmaking in the biopharma industry since 2010
Analysis of co-development deal structure
Case studies of real-life co-development deals
Comprehensive listing of co-development deals since 2010
Access to co-development contract documents
Key financial benchmarks for headline, upfront, milestone and royalty rates
The leading co-development deals by value since 2010
Most active co-development dealmakers since 2010
The leading co-development partnering resources
In Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 available deals and contracts are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive access to available contract documents for co-development deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How do milestone align with clinical stage development phases?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 provides the reader with the following key benefits:
In-depth understanding of co-development deal trends since 2010
Analysis of the structure of co-development agreements with numerous real life case studies
Comprehensive listing of all co-development deals since 2010, together with deal terms, value and press release
Comprehensive access to actual co-development contracts entered into by the world's life science companies
Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
Insight into the terms included in a co-development agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Read the full report: http://www.reportlinker.com/p02861664-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article